argenx SE (ARGNF) reports robust growth with $489 million in operating income, despite facing an operating loss and competitive pressures in the myasthenia gravis market.
Argenx SE Alphatec and Olin have been highlighted in this Screen of The Week article.
With the advent of a strong fourth quarter, it's prudent to invest in stocks exhibiting solid earnings acceleration such as Argenx, Alphatec Holdings and Olin Corporation.